RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?

Publisher： Karger

E-ISSN： 1423-0232|88|4|257-260

ISSN： 0030-2414

Source： Oncology, Vol.88, Iss.4, 2014-12, pp. : 257-260

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Editorial: Combination Cytokine Blockade: The Way Forward in Therapy for Rheumatoid Arthritis?

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 1, 2015-01 ,pp. : 14-16

John Wiley & Sons Inc

Access to resources Recommend Favorite

The ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) Trial: A Step Forward in the Treatment of Early Breast Cancer

By  

Reviews on Recent Clinical Trials, Vol. 1, Iss. 3, 2006-09 ,pp. : 207-215

Bentham Science Publishers

Access to resources Recommend Favorite

Yet another step forward!

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 1, 2018-01 ,pp. : 22-22

John Wiley & Sons Inc

Access to resources Recommend Favorite

Identification of Responders to Sorafenib in Hepatocellular Carcinoma: Is Tumor Volume Measurement the Way Forward?

By  

Oncology, Vol. 86, Iss. 4, 2014-04 ,pp. : 191-198

Karger

Access to resources Recommend Favorite

Expression of RANK-ligand in prostate cancer cell lines

By Penno Hendrik   Nilsson Olle   Brandstrom Helena   Winqvist Ola   Ljunggren Osten  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 69, Iss. 1, 2009-02 ,pp. : 151-155

Informa Healthcare

Access to resources Recommend Favorite